Lent Appeal: The Vicar's Leprosy Fund
A man with leprosy came to him and begged him on his knees,
“If you are willing, you can make me clean.”
Mark 1: 40
“If you are willing, you can make me clean.”
Mark 1: 40
Lent is a season not for inwardness, but for the work of God. It is a time for generosity and outwardness.
This year I am inviting members of St Paul's to give generously to counter the scourge of leprosy. It is a cause that is dear to my heart that is so easily ignored. Through the agency of the Order of St Lazarus's Charitable Trust (Registered Charity No: 286918), to whose Trustees I am an advisor, we will ensure that essential support is provided in India, sub-Saharan Africa and Latin America. If you will skip lunch, or give up something on which you spend money regularly, perhaps you will instead give that money to our Lent Appeal 2024. Thank you in anticipation for your generosity.
Alan Gyle
Vicar and Almoner of the Order of St Lazarus (Grand Priory of England & Wales)
You may not know much about leprosy...
While the disease of Leprosy is familiar to us in the pages of the New Testament, many don't know that it is still a scourge in the modern world. It is is a bacterial disease, its bacillus being closely related to that which causes tuberculosis. The leprosy bacillus grows extremely slowly, dividing only once about every 14 days, so the incubation period of the disease is very long; the treatment is concomitantly slow, and determining whether a patient is cured of leprosy may well take as many years as to decide that a patient is cured of cancer, or even longer.
When the first really cheap and effective treatment for leprosy was introduced in 1946, no relapse cases were observed for about 10-15 years. When these appeared they were shown to be the result of specific drug resistance, the drug having been administered on its own. However, in 1980, after extensive research, a modern multi-drug treatment was devised which appeared to rule out any drug resistance, provided the drugs in the new treatment were taken properly. Proper drug administration, however, is far from easy to guarantee, given the conditions in which most leprosy patients live: in remote villages and, frequently, without motivating encouragement, either to be rigorous about daily treatment or to attend clinics regularly. But more than that, in the worst cases of leprosy, where the body has no effective immunological defence, the skin provides the perfect culture medium for the leprosy bacilli, which can be there in billions. Where bacilli are present in such numbers in the skin and in the peripheral nerves it is not surprising that some of them are 'asleep' (i.e. not responsive to the drugs). It is thus uncertain for how long treatment needs to be administered to ensure a cure in the severest types of leprosy.
Unfortunately, the treatment instituted in 1980 has been so successful, and so many Ministries of Health are unpopular with governments because of the sums of money they need to spend, that it is not surprising governments want to reduce the length of treatment. Those involved in devising the multi-drug therapy advise that it be administered for a minimum of two years, and preferably for a much longer period, depending upon how badly infected the patient. But the World Health Organisation (WHO) has gradually been reducing the recommended length of treatment; it is currently one year for severe cases. It would appear, therefore, that the wish is to get as many “cured” patients through their books as possible, relapse cases going unrecorded or being treated as new patients.
Because leprosy bacilli are so slowly destroyed in the body their poisons can still cause immunological reactions – inflammation and damage inside nerves, and inside the front of the eye, etc. – years after successful treatment has been completed. Such cases are not being properly looked after.
This year I am inviting members of St Paul's to give generously to counter the scourge of leprosy. It is a cause that is dear to my heart that is so easily ignored. Through the agency of the Order of St Lazarus's Charitable Trust (Registered Charity No: 286918), to whose Trustees I am an advisor, we will ensure that essential support is provided in India, sub-Saharan Africa and Latin America. If you will skip lunch, or give up something on which you spend money regularly, perhaps you will instead give that money to our Lent Appeal 2024. Thank you in anticipation for your generosity.
Alan Gyle
Vicar and Almoner of the Order of St Lazarus (Grand Priory of England & Wales)
You may not know much about leprosy...
While the disease of Leprosy is familiar to us in the pages of the New Testament, many don't know that it is still a scourge in the modern world. It is is a bacterial disease, its bacillus being closely related to that which causes tuberculosis. The leprosy bacillus grows extremely slowly, dividing only once about every 14 days, so the incubation period of the disease is very long; the treatment is concomitantly slow, and determining whether a patient is cured of leprosy may well take as many years as to decide that a patient is cured of cancer, or even longer.
When the first really cheap and effective treatment for leprosy was introduced in 1946, no relapse cases were observed for about 10-15 years. When these appeared they were shown to be the result of specific drug resistance, the drug having been administered on its own. However, in 1980, after extensive research, a modern multi-drug treatment was devised which appeared to rule out any drug resistance, provided the drugs in the new treatment were taken properly. Proper drug administration, however, is far from easy to guarantee, given the conditions in which most leprosy patients live: in remote villages and, frequently, without motivating encouragement, either to be rigorous about daily treatment or to attend clinics regularly. But more than that, in the worst cases of leprosy, where the body has no effective immunological defence, the skin provides the perfect culture medium for the leprosy bacilli, which can be there in billions. Where bacilli are present in such numbers in the skin and in the peripheral nerves it is not surprising that some of them are 'asleep' (i.e. not responsive to the drugs). It is thus uncertain for how long treatment needs to be administered to ensure a cure in the severest types of leprosy.
Unfortunately, the treatment instituted in 1980 has been so successful, and so many Ministries of Health are unpopular with governments because of the sums of money they need to spend, that it is not surprising governments want to reduce the length of treatment. Those involved in devising the multi-drug therapy advise that it be administered for a minimum of two years, and preferably for a much longer period, depending upon how badly infected the patient. But the World Health Organisation (WHO) has gradually been reducing the recommended length of treatment; it is currently one year for severe cases. It would appear, therefore, that the wish is to get as many “cured” patients through their books as possible, relapse cases going unrecorded or being treated as new patients.
Because leprosy bacilli are so slowly destroyed in the body their poisons can still cause immunological reactions – inflammation and damage inside nerves, and inside the front of the eye, etc. – years after successful treatment has been completed. Such cases are not being properly looked after.